FDA Logo links to FDA home page
Center for Biologics Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Biologics Evaluation and Research
 HHS Logo links to Department of Health and Human Services website

FDA Home Page | CBER A-Z Index | CBER Search | Contact CBER | CBER Home Page

horizontal rule
CBER links to product areas Blood Vaccines Cellular/Gene Therapy Tissue Devices
CBER links Products Industry Healthcare Reading Room Meetings What's New
horizontal rule

Transmissible Spongiform Encephalopathies Advisory Committee

horizontal rule

June 1-2, 2000 Meeting

Date and Time

The meeting will be held on June 1, 2000, from 8:30 am to 5:30 pm and on June 2, 2000, from 8:30 am to 3:30 pm.

Location

Holiday Inn-Gaithersburg, Ballroom, 2 Montgomery Village Avenue, Gaithersburg, MD. 20879, 301-948-8900.

Contact Person

William Freas or Sheila D. Langford, 301-827-0314. Please call the Information Line for up-to-date information on this meeting.

Agenda

On June 1, 2000, the committee will discuss policies for deferral of blood and plasma donors because of their possible exposure to the agent of bovine spongiform encephalopathy (BSE). On June 2, 2000, the committee will discuss the scientific merit of leukoreduction as a method to reduce the theoretical risk of Creutzfeldt-Jakob Disease (CJD) and/or new variant CJD (nvCJD) in blood and blood components for transfusions as well as plasma for manufacture into derivatives. In the afternoon the committee will receive an update on the regulatory status of human dura mater.

Oral Presentations

On June 1, 2000, between approximately 1:30 - 2:00 pm and 3:10 to 3:25 pm, and on June 2, 2000, between approximately 10:45 to 11:15 am and 1:45 to 2:00 pm oral presentations from the public will be scheduled. Those desiring to make formal oral presentations should notify the contact person before May 22, 2000.

Closed Committee Delibrations

On June 1, 2000, from 5:15 to 5:30 pm the meeting will be closed to permit discussion and review of trade secret and/or confidential information (5 U.S.C. 552b (c) (4)).

 

 
horizontal rule